_:n3902da1a51704c2ab353a92ecaa8e3f2xb0
<http://schema.org/description>
"One day after Ocular Therapeutix sent FDA a detailed response highlighting manufacturing improvements, FDA rejected its application for Dextenza, a new drug designed to alleviate post-operative eye pain."
<https://www.biopharminternational.com/view/gmp-issues-derail-drug-approval-second-time>